Clinical trial
A Study of the Effectiveness and Safety of Risperidone in the Treatment of…
NCT00249145 · Janssen Pharmaceutica N.V., Belgium, Industry · Completed
Key facts
| NCT number | NCT00249145 |
|---|---|
| Title | A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia |
| Official title | Risperidone in the Treatment of Behavioral Disturbances in Demented Patients: an International, Multicenter, Placebo-controlled, Double-blind, Parallel-group Trial Using Haloperidol as Internal Reference |
| Lead sponsor | Janssen Pharmaceutica N.V., Belgium, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Dementia, Alzheimer Disease, Vascular |
| Intervention type | Drug |
| Interventions | risperidone |
| Enrollment | 349 |
| Start date | Apr 1, 1995 |
| Completion | Dec 1, 1996 |
| First posted | Nov 7, 2005 |
| Last update posted | Jan 14, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: